Evidence map›Paper›PMID 37405544›Full record

ArticleJournal of clinical immunology2023

Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults.

Aleha Pillay, Avani Yeola, Fiona Tea, Martina Denkova, Samuel Houston, Rebecca Burrell, Vera Merheb, Fiona X Z Lee, Joseph A Lopez, Lilly Moran and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 1 country.

Aleha PillayBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Avani YeolaBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Fiona TeaBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Martina DenkovaBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Samuel HoustonBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Rebecca BurrellSchool of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Vera MerhebBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Fiona X Z LeeBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Joseph A LopezBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Lilly MoranKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Ajay JadhavKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Katrina SterlingKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Catherine L LaiKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Tennille L VitaglianoKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Anupriya AggarwalThe Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
Dan CatchpooleKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Nicholas WoodKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Tri Giang PhanGarvan Institute of Medical Research, Sydney, New South Wales, Australia.
Ralph NananCharles Perkins Center and Sydney Medical School Nepean, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
Peter HsuKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Stuart G TurvilleThe Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia.
Philip N BrittonKids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Fabienne BrilotBrain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia. Fabienne.brilot@sydney.edu.au.ORCID http://orcid.org/0000-0002-7025-2276
Children's Hospital at Westmead · AUThe University of Sydney · AUUNSW Sydney · AUGarvan Institute of Medical Research · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although a more efficient adaptive humoral immune response has been proposed to underlie the usually favorable outcome of pediatric COVID-19, the breadth of viral and vaccine cross-reactivity toward the ever-mutating Spike protein among variants of concern (VOCs) has not yet been compared between children and adults. We assessed antibodies to conformational Spike in COVID-19-naïve children and adults vaccinated by BNT162b2 and ChAdOx1, and naturally infected with SARS-CoV-2 Early Clade, Delta, and Omicron. Sera were analyzed against Spike including naturally occurring VOCs Alpha, Beta, Gamma, Delta, and Omicron BA.1, BA.2, BA.5, BQ.1.1, BA2.75.2, and XBB.1, and variants of interest Epsilon, Kappa, Eta, D.2, and artificial mutant Spikes. There was no notable difference between breadth and longevity of antibody against VOCs in children and adults. Vaccinated individuals displayed similar immunoreactivity profiles across variants compared with naturally infected individuals. Delta-infected patients had an enhanced cross-reactivity toward Delta and earlier VOCs compared to patients infected by Early Clade SARS-CoV-2. Although Omicron BA.1, BA.2, BA.5, BQ.1.1, BA2.75.2, and XBB.1 antibody titers were generated after Omicron infection, cross-reactive binding against Omicron subvariants was reduced across all infection, immunization, and age groups. Some mutations, such as 498R and 501Y, epistatically combined to enhance cross-reactive binding, but could not fully compensate for antibody-evasive mutations within the Omicron subvariants tested. Our results reveal important molecular features central to the generation of high antibody titers and broad immunoreactivity that should be considered in future vaccine design and global serosurveillance in the context of limited vaccine boosters available to the pediatric population.

Indexed as

COVID-19VaccinesAdultAntibodiesAntibody FormationBNT162 VaccineChildHumansSARS-CoV-2AntibodiesBNT162 VaccineVaccinesadult COVID-19cross-reactivityepistasisPediatric COVID-19SARS-CoV-2Spike antibodyvaccinevariant of concern

Identifiers

PMID37405544
PMCPMC10661752
OpenAlexW4383186427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.